Company Overview - IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases [3] - The company's lead program, INB-100, targets acute myeloid leukemia using haplo-matched allogeneic γδ T cells post-hematopoietic stem cell transplant [3] - IN8bio is also advancing autologous DeltEx DRI γδ T cells for glioblastoma in its INB-200 and INB-400 programs, along with INB-600, which focuses on novel γδ T cell engagers for oncology and autoimmune indications [3] Conference Participation - William Ho, CEO and co-founder of IN8bio, will present at the Noble Emerging Growth Virtual Equity Conference on February 5, 2026, at 3:00 p.m. ET [1] - The company will also participate in the IO360° Conference on February 12, 2026, where it will present on its DeltEx Drug Resistant Immunotherapy (DRI) approach to solid tumors and share results from a Phase 1/2 study in newly diagnosed glioblastoma [2]